| Literature DB >> 25567242 |
Birgit Bjerre Høyer1, Cecilia Høst Ramlau-Hansen, Carsten Obel, Henning Sloth Pedersen, Agnieszka Hernik, Victor Ogniev, Bo A G Jönsson, Christian H Lindh, Lars Rylander, Anna Rignell-Hydbom, Jens Peter Bonde, Gunnar Toft.
Abstract
BACKGROUND: In animal studies, perfluorinated alkyl substances affect growth and neuro-behavioural outcomes. Human epidemiological studies are sparse. The aim was to investigate the association between pregnancy serum concentrations of perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) and offspring behaviour and motor development at 5-9 years of age.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25567242 PMCID: PMC4298045 DOI: 10.1186/1476-069X-14-2
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Characteristics of mothers and their children according to country
| Characteristics | Combined | Greenland | Ukraine | Poland |
|---|---|---|---|---|
| (N = 1,106) | (n = 526) | (n = 491) | (n = 89) | |
|
| ||||
| DCDQ-score (points) a | 52 (40–69) | 63 (51–75) | 46 (37–55) | 64 (52–73) |
| Missing, n (%) | 298 (27) | 289 (55) | 6 (1) | 3 (3) |
| SDQ-score (points) a | 7 (2–15) | 7 (2–14) | 8 (4–14) | 8 (2–15) |
| Missing, n (%) | 7 (1) | 6 (1) | 0 (0) | 1 (1) |
| SDQ, n (%) | ||||
| Normal | 954 (86) | 455 (88) | 424 (86) | 75 (85) |
| Borderline | 82 (7) | 34 (6) | 40 (8) | 8 (9) |
| Abnormal | 63 (6) | 31 (6) | 27 (6) | 5 (6) |
| Hyperactivity, n (%) | ||||
| Normal | 967 (87) | 477 (91) | 425 (86) | 65 (73) |
| Borderline | 70 (6) | 20 (4) | 42 (9) | 8 (9) |
| Abnormal | 62 (6) | 23 (4) | 24 (5) | 15 (17) |
| Missing, n (%) | 7 (1) | 6 (1) | 0 (0) | 1 (1) |
|
| ||||
| Maternal age at pregnancy, years | 26 (20–35) | 26 (20–37) | 24 (20–32) | 29 (26–34) |
| Missing, n (%) | 62 (6) | 38 (7) | 24 (5) | 0 (0) |
| Maternal pre-pregnancy BMI, kg/m2 a | 22 (19–28) | 24 (20–30) | 21 (18–26) | 21 (19–24) |
| Parity, no. (%) | ||||
| 0 | 650 (59) | 167 (33) | 399 (81) | 84 (94) |
| 1 or more | 432 (39) | 335 (67) | 92 (19) | 5 (6) |
| Missing, n (%) | 24 (2) | 24 (5) | 0 (0) | 0 (0) |
| Maternal cotinine level during pregnancy, no. (%) | ||||
| >10 ng/ml - smoker | 374 (34) | 296 (56) | 76 (15) | 2 (2) |
| ≤10 ng/ml – non-smoker | 732 (66) | 230 (44) | 415 (85) | 87 (98) |
| Maternal alcohol consumption at conception, no. (%) | ||||
| ≤7 drinks/week | 1,040 (94) | 465 (88) | 491 (100) | 84 (94) |
| >7 drinks/week | 66 (6) | 61 (12) | 0 (0) | 5 (6) |
| Missing b | 582 (500) | 261 (50) | 307 (63) | 14 (16) |
| Maternal educational level, left school at age, no. (%) | ||||
| <18 years | 356 (32) | 217 (46) | 139 (28) | 0 (0) |
| ≥18 years | 621 (56) | 249 (54) | 293 (68) | 79 (100) |
| Missing, n (%) | 129 (12) | 60 (11) | 59 (12) | 10 (11) |
|
| ||||
| Sex, no. (%) | ||||
| Male | 595 (54) | 282 (53) | 260 (53) | 53 (60) |
| Female | 505 (45) | 241 (46) | 228 (46) | 36 (40) |
| Missing, n (%) | 6 (1) | 3 (1) | 3 (1) | 0 (0) |
| Total breastfeeding duration, no. (%) | ||||
| 0 months | 62 (6) | 17 (4) | 43 (9) | 2 (2) |
| <6 months | 302 (27) | 120 (25) | 163 (33) | 19 (22) |
| 6–12 months | 334 (30) | 124 (26) | 175 (36) | 35 (39) |
| >12 months | 354 (32) | 214 (45) | 107 (22) | 33 (37) |
| Missing, n (%) | 54 (5) | 51 (10) | 3 (1) | 0 (0) |
| Gestational age, no. (%) | ||||
| ≥37 weeks | 1,043 (95) | 499 (95) | 479 (98) | 65 (94) |
| <37 weeks | 37 (3) | 24 (5) | 9 (2) | 4 (6) |
| Missing, n (%) | 26 (2) | 3 (1) | 3 (1) | 20 (22) |
| Gestational age at blood sample, weeks a | 39 (38–41) | 25 (13–37) | 23 (9–40) | 33 (27–37) |
| Birth weight, grams a | 3,430 (2,800-4,130) | 3,600 (2,840-4,370) | 3,285 (2,800-3,800) | 3,460 (2,880-4,000) |
| Age at follow-up, years a | 7 (7–9) | 8 (7–9) | 7 (7–8) | 8 (7–8) |
| Missing, n (%) | 58 (5) | 53 (10) | 5 (1) | 0 (0) |
BMI, body mass index; DCDQ, developmental coordination disorder questionnaire; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; SDQ, strength and difficulties questionnaire. All percentages are based on complete-case data. a Median (10th-90th percentile). b Missing alcohol information was set to 0 intake.
Range (ng/ml) of PFOS/PFOA plasma concentrations, by tertile, in pregnant women
| Exposure | Tertile | Combined | Greenland | Ukraine | Poland |
|---|---|---|---|---|---|
| (N = 1,106) | (n = 526) | (n = 491) | (n = 89) | ||
|
| Median (10th-90th percentile) | 10.0 (3.6, 27,4) | 20.3 (12.0-37.0) | 5.0 (2.9-8.2) | 8.0 (5.3-12.7) |
| Low tertile | 0.7-6.2 | 4.1-16.8 | 0.7-4.2 | 2.5-7.0 | |
| Medium tertile | 6.2-16.6 | 16.8-23.9 | 4.2-5.9 | 7.1-9.6 | |
| High tertile | 16.6-87.3 | 23.9-87.3 | 5.9-18.1 | 9.7-21.3 | |
|
| Median (10th-90th percentile) | 1.4 (0.7, 3.0) | 1.8 (1.0-3.1) | 1.0 (0.5-1.7) | 2.7 (1.5-4.3) |
| Low tertile | 0.2-1.1 | 0.5-1.5 | 0.2-0.8 | 1.0-2.2 | |
| Medium tertile | 1.1-1.9 | 1.5-2.2 | 0.8-1.1 | 2.2-3.1 | |
| High tertile | 1.9-9.8 | 2.2-5.1 | 1.1-9.8 | 3.1-9.8 |
PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate.
Associations between pregnancy levels of PFOS/PFOA (ng/ml) and offspring DCDQ-score
| Exposure | Combined d (N = 1,106) | Greenland (n = 526) | Ukraine (n = 491) | Poland (n = 89) | |
|---|---|---|---|---|---|
| β (95% CI) | β (95% CI) | β (95% CI) | β (95% CI) | ||
|
| Low | ref | ref | ref | ref |
| Medium | −0.4 (−1.9, 1.2) | −1.2 (−3.0, 0.7) | 1.4 (−0.2, 3.1) | −0.3 (−6.0, 5.3) | |
| High | −1.7 (−3.8, 0.5) | −0.7 (−2.6, 1.2) | 0.6 (−1.1, 2.2) | −2.1 (−7.8, 3.5) | |
| Continuousc | −0.1 (−1.2, 1.1) | −0.2 (−1.9, 1.4) | 0.5 (−1.0, 2.0) | −2.4 (−9.1, 4.3) | |
|
| Low | ref | ref | ref | ref |
| Medium | −0.6 (−1.9, 0.7) | −1.2 (−3.0, 0.7) | −0.2 (−1.8, 1.4) | 1.5 (−4.1, 7.1) | |
| High | −0.4 (−1.9, 1.1) | −0.1 (−2.0, 1.7) | −1.2 (−2.8, 0.5) | −3.7 (−9.3, 1.9) | |
| Continuousc | −0.2 (−1.2, 0.9) | 0.8 (−0.8, 2.5) | −0.6 (−1.9, 0.8) | −2.7 (−8.3, 2.8) | |
CI, confidence interval; DCDQ, developmental coordination disorder questionnaire; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; Ref, referece group.
aAdjusted for: maternal cotinine level during pregnancy, maternal alcohol consumption at conception, maternal age at pregnancy, gestational age at blood-sampling and child sex. bDCDQ score range from 15 to 75 (low scores indicate motor problems). cβ = the change in score according to one natural-log unit increase in PFOA and PFOS. dadditionally adjusted for country.
Associations between pregnancy levels of PFOS/PFOA (ng/ml) and offspring SDQ-total and hyperactivity score
| Combined (N = 1,106) e | Greenland (n = 526) | Ukraine (n = 491) | Poland (n = 89) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Scale (score range) | Difference | 95% CI | Difference | 95% CI | Difference | 95% CI | Difference | 95% CI | ||
|
|
| Low | Ref | - | Ref | - | Ref | - | Ref | - |
| Medium | 0.3 | −0.5, 1.0 | 0.7 | −0.4, 1.7 | −0.9 | −1.9, 0.1 | 0.8 | −1.9, 3.4 | ||
| High | 0.7 | −0.2, 1.5 | 0.5 | −0.6, 1.5 | −0.3 | −1.3, 0.7 | 1.8 | −0.8, 4.5 | ||
| Continuousd | 0.1 | −0.5, 0.7 | 0.3 | −0.6, 1.3 | −0.5 | −1.3, 0.4 | 2.1 | −0.4, 4.7 | ||
|
| Low | Ref | - | Ref | - | Ref | - | Ref | - | |
| Medium | 0.1 | −0.3, 0.4 | 0.5 | 0.0, 1.0 | −0.3 | −0.7, 0.1 | 1.1 | −0.4, 2.6 | ||
| High | 0.5 | 0.1, 0.9 | 0.6 | 0.1, 1.1 | −0.2 | −0.6, 0.2 | 0.9 | −0.6, 2.4 | ||
| Continuousd | 0.3 | 0.0, 0.5 | 0.5 | 0.1, 0.9 | −0.1 | −0.5, 0.2 | 1.2 | −0.3, 2.6 | ||
|
|
| Low | Ref | - | Ref | - | Ref | - | Ref | - |
| Medium | 0.1 | −1.0, 0.8 | 1.3 | 0.3, 2.4 | −1.0 | −2.0, 0.0 | −0.1 | −2.7, 2.5 | ||
| High | 1.1 | −0.1, 2.3 | 1.1 | 0.1, 2.2 | −1.0 | −2.2-0.0 | 2.0 | −0.6, 4.6 | ||
| Continuousd | 0.3 | −0.3, 1.0 | 1.0 | 0.1, 2.0 | −1.0 | −1.6, 0.2 | 2.6 | −0.5, 5.7 | ||
|
| Low | Ref | - | Ref | - | Ref | - | Ref | - | |
| Medium | 0.1 | −0.3-0.5 | 0.4 | −0.1, 0.8 | −0.2 | −0.6, 0.2 | 0.9 | −0.5, 2.4 | ||
| High | 0.5 | 0.0, 1.0 | 0.3 | −0.2, 0.7 | −0.1 | −0.5, 0.3 | 1.3 | −0.1, 2.8 | ||
| Continuousd | 0.2 | −0.1, 0.5 | 0.3 | −0.1, 0.7 | −0.1 | −0.4, 0.3 | 1.5 | −0.3, 3.2 | ||
CI, confidence interval; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; Ref, reference group; SDQ, strength and difficulties questionnaire.
aAdjusted for: maternal cotinine level during pregnancy, maternal alcohol consumption at conception, maternal age at pregnancy, gestational age at blood-sampling and child sex. bHigh scores indicate behavioural problems. cHigh scores indicate more hyperactive behaviour. dβ = the change in score according to one natural-log unit increase in PFOA and PFOS. eAdditionally adjusted for country.
Associations between pregnancy levels of PFOS/PFOA (ng/ml) and offspring behavioural and hyperactivity problems
| Scale | Combined e | Greenland | Ukraine | Poland |
|---|---|---|---|---|
| Adjusted OR (95% CI) | Adjusted OR (95% CI) | Adjusted OR (95% CI) | Adjusted OR (95% CI) | |
| (N = 1,106) | (n = 526) | (n = 491) | (n = 89) | |
|
| ||||
| PFOS | ||||
| Low | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| Medium | 1.1 (0.5, 2.5) | 1.7 (0.7, 4.0) | 0.6 (0.2, 1.6) | - |
| High | 1.5 (0.5, 4.8) | 0.8 (0.3, 2.2) | 0.6 (0.2, 1.5) | - |
| Continuousd | 1.1 (0.6, 2.0) | 0.9 (0.4, 2.1) | 1.0 (0.4, 2.5) | - |
| PFOA | ||||
| Low | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| Medium | 2.0 (1.0, 4.2) | 2.7 (1.0, 7.5) | 1.3 (0.5, 3.5) | - |
| High | 2.7 (1.2, 6.3) | 1.9 (0.7, 5.4) | 1.5 (0.6, 4.2) | - |
| Continuousd | 1.5 (0.9, 2.6) | 2.1 (0.8, 5.2) | 1.0 (0.4, 2.3) | - |
|
| ||||
| PFOS | ||||
| Low | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | - |
| Medium | 1.2 (0.5, 2.5) | 1.1 (0.4, 3.4) | 1.2 (0.4, 3.3) | - |
| High | 1.4 (0.4, 4.9) | 1.3 (0.4, 3.9) | 1.4 (0.5, 3.9) | - |
| Continuousd | 1.7 (0.9, 3.2) | 1.9 (0.7, 4.8) | 1.3 (0.5, 3.4) | - |
| PFOA | ||||
| Low | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | - |
| Medium | 0.8 (0.4, 2.0) | 5.4 (1.1, 25.6) | 0.8 (0.3, 2.3) | - |
| High | 3.1 (1.3, 7.2) | 6.3 (1.3, 30.1) | 0.9 (0.3, 2.4) | - |
| Continuousd | 1.6 (0.9, 2.8) | 3.6 (1.2, 3.7) | 0.8 (0.3, 1.9) | - |
CI, confidence interval; OR, odds ratio; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; SDQ, strength and difficulties questionnaire; Ref, reference group.
aAdjusted for maternal cotinine level during pregnancy, maternal alcohol consumption at conception, child sex, maternal age at pregnancy and gestational age at blood sampling.
bSDQ cut-offs: normal and borderline (0 to 16) versus abnormal (17 to 40).
cHyperactivity cut-offs: normal and borderline (0 to 6) versus (7 to 10).
dThe change in OR according to one natural logarithm increase in exposures.
eAdditionally adjusted for country.